Lepodisiran vs Zerlasiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: LPA gene / apolipoprotein(a) mRNA · full Atherosclerotic Cardiovascular Disease pipeline

Lepodisiran

Developed by Eli Lilly and partners

Phase 3 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT05565742 · Phase 2 · completed

The trial randomized 320 participants and used double blinding with a placebo control. Its primary endpoint was a statistically significant reduction in Lp(a) versus placebo for all doses, but Lp(a) is a laboratory biomarker rather than a direct clinical outcome, so the findings provide moderate evidence.

Next expected readout: March 2027 · NCT07914738 (registry estimate)

Reported efficacy

Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): Percent Change From Baseline in Time Averaged Lipoprotein(a) [Lp(a)] Over Days 60-180 (Baseline, Days 60 - 180): 16 mg LY3819469 -39.0% ± 7.37 vs 96 mg LY3819469 -74.4% ± 2.16 vs 400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) -93.7% ± 0.38 vs Placebo 3.1% ± 8.99; p=<0.001 (16 mg LY3819469 vs Placebo), p=<0.001 (96 mg LY3819469 vs Placebo), p=<0.001 (400 mg LY3819469 and 400 mg LY3819469 + Placebo (400 mg LY3819469 Pooled) vs Placebo) (met)

Result source: NCT05565742

Zerlasiran

Developed by Silence Therapeutics

Phase 2 in Atherosclerotic Cardiovascular DiseaseRNAi (siRNA)
Partial signal

NCT05537571 · Phase 2 · completed

The trial randomized participants to three zerlasiran regimens or placebo and masked both participants and investigators, with 180 participants enrolled. The primary endpoint was met for all active regimens, with statistically significant reductions in lipoprotein(a) versus pooled placebo; however, because the primary endpoint was a surrogate biomarker rather than a clinical outcome, this evidence is rated moderate.

Reported efficacy

Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36: Time-averaged Percent Change In Lipoprotein(a) Molar Concentration From Baseline to Week 36 (Week 36): SLN360 300 mg Q16W -80.5% (Standard Error 1.99) | SLN360 300 mg Q24W -79.1% (Standard Error 1.94) | SLN360 450 mg Q24W -83.3% (Standard Error 1.92) vs Pooled Placebo 2.3% (Standard Error 1.88) (met)

Result source: NCT05537571

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLepodisiranZerlasiran
LDL-C, % change—Trial running · NCT06292013-14.7% vs 9.3%−24 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -17% vs 8.9% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -15.5% vs 9.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -19.3% vs 9.3% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -16.8% vs 9.3% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -20.9% vs 8.9% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -18.5% vs 8.9% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -22.3% vs 9.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -20.1% vs 9.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
Non-HDL-C, % change—Trial running · NCT06292013—Not reported
ApoB, % change-9.1% vs 4.3%−13.4 vs placebo400 mg · wk 77.14 · n 69NCT05565742
19 other results
  • -0.9% vs 4.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -10.4% vs 4.3% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -4.6% vs 4.3% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -14% vs 1.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -9% vs 1.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -0.6% vs 4.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -8.1% vs 4.3% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -13.8% vs 1.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -9.6% vs 1.3% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -11.8% vs 0.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • 1.4% vs 4.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -2.9% vs 4.3% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -7.6% vs 1.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -7% vs 1.3% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -10.2% vs 0.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
-16.4% vs -3.8%−12.6 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -18% vs -4% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -18.6% vs -3.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -15% vs -3.8% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -10.9% vs -3.8% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -16.4% vs -4% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -12.6% vs -4% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -16.9% vs -3.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -13.5% vs -3.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571
Lp(a), % change-74.4% vs 3.1%−77.5 vs placebo96 mg · n 74NCT05565742
25 other results
  • -39% vs 3.1% 16 mg · n 36 · Phase 2 · primary NCT05565742
  • -73.8% vs 1.3% 400 mg · wk 77.14 · n 69 · Phase 2 · secondary NCT05565742
  • -52.8% vs 1.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -91.1% vs -0.9% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -68.1% vs -0.9% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -96.8% vs -0.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -84.9% vs -0.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -95% vs 0.3% 400 mg · n 69 · Phase 2 · secondary NCT05565742
  • -76.7% vs 0.3% 400 mg · n 72 · Phase 2 · secondary NCT05565742
  • -45.1% vs 1.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -67.7% vs -0.9% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -84.8% vs -0.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -65.3% vs 2.2% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -80.4% vs 2.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • -77.4% vs 0.3% 96 mg · n 74 · Phase 2 · secondary NCT05565742
  • -18.7% vs 1.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -30.8% vs -0.9% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -47.7% vs -0.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -30.5% vs 2.2% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -46.2% vs 2.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
  • -38.7% vs 0.3% 16 mg · n 36 · Phase 2 · secondary NCT05565742
-83.3% vs 2.3%−85.6 vs placebo450 mg Q24W · wk 36 · n 45NCT05537571
8 other results
  • -80.5% vs 2.3% 300 mg Q16W · wk 36 · n 42 · Phase 2 · primary NCT05537571
  • -79.1% vs 2.3% 300 mg Q24W · wk 36 · n 44 · Phase 2 · primary NCT05537571
  • -76% vs 1.1% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -81.5% vs 1.5% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -78% vs 1.1% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -70.7% vs 1.1% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -81.6% vs 1.5% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -77.2% vs 1.5% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
3-point MACE (% with event)—Trial running · NCT06292013—Not reported

LDL-C, % change

Lepodisiran
—Trial running · NCT06292013
Zerlasiran
-14.7% vs 9.3%−24 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -17% vs 8.9% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -15.5% vs 9.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -19.3% vs 9.3% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -16.8% vs 9.3% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -20.9% vs 8.9% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -18.5% vs 8.9% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -22.3% vs 9.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -20.1% vs 9.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571

Non-HDL-C, % change

Lepodisiran
—Trial running · NCT06292013
Zerlasiran
—Not reported

ApoB, % change

Lepodisiran
-9.1% vs 4.3%−13.4 vs placebo400 mg · wk 77.14 · n 69NCT05565742
19 other results
  • -0.9% vs 4.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -10.4% vs 4.3% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -4.6% vs 4.3% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -14% vs 1.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -9% vs 1.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -12.6% vs 1.3% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -13.9% vs 0.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -0.6% vs 4.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -8.1% vs 4.3% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -13.8% vs 1.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -9.6% vs 1.3% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -11.8% vs 0.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • 1.4% vs 4.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -2.9% vs 4.3% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -7.6% vs 1.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -7% vs 1.3% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -10.2% vs 0.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
Zerlasiran
-16.4% vs -3.8%−12.6 vs placebo450 mg Q24W · wk 60 · n 45NCT05537571
8 other results
  • -18% vs -4% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -18.6% vs -3.6% 450 mg Q24W · wk 36 · n 45 · Phase 2 · secondary NCT05537571
  • -15% vs -3.8% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -10.9% vs -3.8% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -16.4% vs -4% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -12.6% vs -4% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571
  • -16.9% vs -3.6% 300 mg Q16W · wk 36 · n 42 · Phase 2 · secondary NCT05537571
  • -13.5% vs -3.6% 300 mg Q24W · wk 36 · n 44 · Phase 2 · secondary NCT05537571

Lp(a), % change

Lepodisiran
-74.4% vs 3.1%−77.5 vs placebo96 mg · n 74NCT05565742
25 other results
  • -39% vs 3.1% 16 mg · n 36 · Phase 2 · primary NCT05565742
  • -73.8% vs 1.3% 400 mg · wk 77.14 · n 69 · Phase 2 · secondary NCT05565742
  • -52.8% vs 1.3% 400 mg · wk 77.14 · n 72 · Phase 2 · secondary NCT05565742
  • -91.1% vs -0.9% 400 mg · wk 51.43 · n 69 · Phase 2 · secondary NCT05565742
  • -68.1% vs -0.9% 400 mg · wk 51.43 · n 72 · Phase 2 · secondary NCT05565742
  • -96.8% vs -0.8% 400 mg · wk 34.29 · n 69 · Phase 2 · secondary NCT05565742
  • -84.9% vs -0.8% 400 mg · wk 34.29 · n 72 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 69 · Phase 2 · secondary NCT05565742
  • -90.5% vs 2.2% 400 mg · wk 25.71 · n 72 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 69 · Phase 2 · secondary NCT05565742
  • -95.4% vs 2.2% 400 mg · wk 8.57 · n 72 · Phase 2 · secondary NCT05565742
  • -95% vs 0.3% 400 mg · n 69 · Phase 2 · secondary NCT05565742
  • -76.7% vs 0.3% 400 mg · n 72 · Phase 2 · secondary NCT05565742
  • -45.1% vs 1.3% 96 mg · wk 77.14 · n 74 · Phase 2 · secondary NCT05565742
  • -67.7% vs -0.9% 96 mg · wk 51.43 · n 74 · Phase 2 · secondary NCT05565742
  • -84.8% vs -0.8% 96 mg · wk 34.29 · n 74 · Phase 2 · secondary NCT05565742
  • -65.3% vs 2.2% 96 mg · wk 25.71 · n 74 · Phase 2 · secondary NCT05565742
  • -80.4% vs 2.2% 96 mg · wk 8.57 · n 74 · Phase 2 · secondary NCT05565742
  • -77.4% vs 0.3% 96 mg · n 74 · Phase 2 · secondary NCT05565742
  • -18.7% vs 1.3% 16 mg · wk 77.14 · n 36 · Phase 2 · secondary NCT05565742
  • -30.8% vs -0.9% 16 mg · wk 51.43 · n 36 · Phase 2 · secondary NCT05565742
  • -47.7% vs -0.8% 16 mg · wk 34.29 · n 36 · Phase 2 · secondary NCT05565742
  • -30.5% vs 2.2% 16 mg · wk 25.71 · n 36 · Phase 2 · secondary NCT05565742
  • -46.2% vs 2.2% 16 mg · wk 8.57 · n 36 · Phase 2 · secondary NCT05565742
  • -38.7% vs 0.3% 16 mg · n 36 · Phase 2 · secondary NCT05565742
Zerlasiran
-83.3% vs 2.3%−85.6 vs placebo450 mg Q24W · wk 36 · n 45NCT05537571
8 other results
  • -80.5% vs 2.3% 300 mg Q16W · wk 36 · n 42 · Phase 2 · primary NCT05537571
  • -79.1% vs 2.3% 300 mg Q24W · wk 36 · n 44 · Phase 2 · primary NCT05537571
  • -76% vs 1.1% 450 mg Q24W · wk 60 · n 45 · Phase 2 · secondary NCT05537571
  • -81.5% vs 1.5% 450 mg Q24W · wk 48 · n 45 · Phase 2 · secondary NCT05537571
  • -78% vs 1.1% 300 mg Q16W · wk 60 · n 42 · Phase 2 · secondary NCT05537571
  • -70.7% vs 1.1% 300 mg Q24W · wk 60 · n 44 · Phase 2 · secondary NCT05537571
  • -81.6% vs 1.5% 300 mg Q16W · wk 48 · n 42 · Phase 2 · secondary NCT05537571
  • -77.2% vs 1.5% 300 mg Q24W · wk 48 · n 44 · Phase 2 · secondary NCT05537571

3-point MACE (% with event)

Lepodisiran
—Trial running · NCT06292013
Zerlasiran
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lepodisiran: 3 of 4 rows · Zerlasiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLepodisiranZerlasiran
Dropout rate
2.9%400 mga
NCT05565742 · Phase 2
show 3 more results
2.8%400 mg
NCT05565742 · Phase 2
0%96 mg
NCT05565742 · Phase 2
2.8%16 mg
NCT05565742 · Phase 2
2.2%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
11.4%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
2.3%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Discontinued due to AEs
—400 mga
NCT05565742 · Phase 2
show 3 more results
—400 mg
NCT05565742 · Phase 2
—96 mg
NCT05565742 · Phase 2
—16 mg
NCT05565742 · Phase 2
0%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
4.5%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
0%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Serious AEs
15.9%400 mga
NCT05565742 · Phase 2
show 3 more results
11.1%400 mg
NCT05565742 · Phase 2
12.2%96 mg
NCT05565742 · Phase 2
2.8%16 mg
NCT05565742 · Phase 2
11.1%450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
14.3%300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
4.5%300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
Most frequent reported AEs
400 mga
injection site reaction 11.6% (placebo 1.4%)
covid-19 7.2% (placebo 10.1%)
nasopharyngitis 7.2% (placebo 8.7%)
NCT05565742 · Phase 2
show 3 more results
400 mg
nasopharyngitis 13.9% (placebo 8.7%)
arthralgia 8.3% (placebo 2.9%)
injection site reaction 8.3% (placebo 1.4%)
NCT05565742 · Phase 2
96 mg
influenza 9.5% (placebo 2.9%)
injection site reaction 8.1% (placebo 1.4%)
nasopharyngitis 8.1% (placebo 8.7%)
NCT05565742 · Phase 2
16 mg
influenza 11.1% (placebo 2.9%)
ovarian cyst 11.1% (placebo 0%)
covid-19 5.6% (placebo 10.1%)
NCT05565742 · Phase 2
450 mg Q24W
injection site reaction 82.2% (placebo 8.7%)
influenza-like illness 15.6% (placebo 0%)
myalgia 15.6% (placebo 4.3%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 2 more results
300 mg Q16W
injection site reaction 83.3% (placebo 8.7%)
malaise 14.3% (placebo 0%)
upper respiratory tract infection 14.3% (placebo 4.3%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
300 mg Q24W
injection site reaction 81.8% (placebo 8.7%)
upper respiratory tract infection 15.9% (placebo 4.3%)
covid-19 13.6% (placebo 13%)
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Zerlasiran

LDL-C -15.5% (n=45) vs 9.6% (n=47) placebo @ 36wk450 mg Q24W
percent change · % of baseline
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
show 8 more results
-17% (n=45) vs 8.9% (n=47) placebo @ 48wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-14.7% (n=45) vs 9.3% (n=47) placebo @ 60wk450 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-22.3% (n=42) vs 9.6% (n=47) placebo @ 36wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-20.1% (n=44) vs 9.6% (n=47) placebo @ 36wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-20.9% (n=42) vs 8.9% (n=47) placebo @ 48wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-18.5% (n=44) vs 8.9% (n=47) placebo @ 48wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-19.3% (n=42) vs 9.3% (n=47) placebo @ 60wk300 mg Q16W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2
-16.8% (n=44) vs 9.3% (n=47) placebo @ 60wk300 mg Q24W
NCT05537571 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lepodisiran's landscape · Zerlasiran's landscape